Literature DB >> 26107195

miR-9 Modulates Osteosarcoma Cell Growth by Targeting the GCIP Tumor Suppressor.

Shao-Wen Zhu1, Jian-Peng Li, Xin-Long Ma, Jian-Xiong Ma, Yang Yang, Yang Chen, Wei Liu.   

Abstract

Osteosarcoma is the most common primary bone tumor in humans, especially in childhood. However, the genetic etiology for its pathogenesis remains elusive. It is known that microRNAs (miRNAs) are involved in the development of tumor progression. Here we show that microRNA-9 (miR-9) is a potential oncogene upregulated in osteosarcoma cells. Knockdown of miR-9 in osteosarcoma resulted in suppressed colony formation and cell proliferation. Further study identified GCIP, a Grap2 and cyclin D interacting protein, as a direct target of miR- 9. In addition, GCIP overexpression activated retinoblastoma 1 (Rb) and suppressed E2F transcriptional target expression in osteosarcoma cells. Moreover, GCIP depletion reversed miR-9 knockdown induced colony formation and cell proliferation suppression. In sum, these results highlight the importance of miR-9 as an oncogene in regulating the proliferation of osteosarcoma by directly targeting GCIP and may provide new insights into the pathogenesis of osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26107195     DOI: 10.7314/apjcp.2015.16.11.4509

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

Review 1.  miRNA signatures in childhood sarcomas and their clinical implications.

Authors:  G M Viera; K B Salomao; G R de Sousa; M Baroni; L E A Delsin; J A Pezuk; M S Brassesco
Journal:  Clin Transl Oncol       Date:  2019-04-04       Impact factor: 3.405

Review 2.  Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Authors:  Chongchong Wang; Juehua Jing; Li Cheng
Journal:  Invest New Drugs       Date:  2018-08-06       Impact factor: 3.850

Review 3.  Anti-miRNA oligonucleotides: A comprehensive guide for design.

Authors:  Joana Filipa Lima; Laura Cerqueira; Ceu Figueiredo; Carla Oliveira; Nuno Filipe Azevedo
Journal:  RNA Biol       Date:  2018-03-23       Impact factor: 4.652

4.  miR-9-3p inhibits glioma cell proliferation and apoptosis by directly targeting FOXG1.

Authors:  Jianwen Zhen; Hengxun Zhang; Hongzhi Dong; Xiaopeng Tong
Journal:  Oncol Lett       Date:  2020-06-11       Impact factor: 2.967

5.  MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells.

Authors:  Ziqiang Zhu; Jinshan Tang; Jianqiang Wang; Gang Duan; Lei Zhou; Xiaoqing Zhou
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

6.  MiR-9 is overexpressed in spontaneous canine osteosarcoma and promotes a metastatic phenotype including invasion and migration in osteoblasts and osteosarcoma cell lines.

Authors:  Joelle M Fenger; Ryan D Roberts; O Hans Iwenofu; Misty D Bear; Xiaoli Zhang; Jason I Couto; Jaime F Modiano; William C Kisseberth; Cheryl A London
Journal:  BMC Cancer       Date:  2016-10-10       Impact factor: 4.430

7.  MicroRNA-9 functions as a tumor suppressor and enhances radio-sensitivity in radio-resistant A549 cells by targeting neuropilin 1.

Authors:  Kai Xiong; Li Hong Shao; Hai Qin Zhang; Linlin Jin; Wei Wei; Zhuo Dong; Yue Quan Zhu; Ning Wu; Shun Zi Jin; Li Xiang Xue
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

8.  Prognostic Value of microRNA-9 in Various Cancers: a Meta-analysis.

Authors:  Yunyuan Zhang; Jun Zhou; Meiling Sun; Guirong Sun; Yongxian Cao; Haiping Zhang; Runhua Tian; Lan Zhou; Liang Duan; Xian Chen; Limin Lun
Journal:  Pathol Oncol Res       Date:  2016-11-14       Impact factor: 3.201

9.  Exosomes containing differential expression of microRNA and mRNA in osteosarcoma that can predict response to chemotherapy.

Authors:  Ji-Feng Xu; Ya-Ping Wang; Shui-Jun Zhang; Yu Chen; Hai-Feng Gu; Xiao-Fan Dou; Bing Xia; Qing Bi; Shun-Wu Fan
Journal:  Oncotarget       Date:  2017-06-06

10.  MicroRNAs with prognostic significance in osteosarcoma: a systemic review and meta-analysis.

Authors:  Dong Cheng; Xubin Qiu; Ming Zhuang; Chenlei Zhu; Hongjun Zou; Zhiwei Liu
Journal:  Oncotarget       Date:  2017-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.